Sangamo BioSciences | SGMO - Gross Profit On Sales


Sangamo BioSciences reported -2.39M in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Bayer EUR 5.35B 1.02B Sep/2025
BioCryst Pharmaceuticals USD -88.88M 202.74M Dec/2024
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Cipla INR 41.64B 6.31B Dec/2025
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 241K 649K Sep/2025
CSL USD 4.46B 2.71B Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Grifols EUR 766.49M 39.74M Dec/2024
Ionis Pharmaceuticals USD 195M 40M Dec/2025
J&J USD 16.6B 118M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Omeros USD -33.16M 18.52M Jun/2024
Pfizer USD 3.54B 7.61B Sep/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Tectonic Therapeutic USD 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025